File Download
Supplementary
-
Citations:
- Appears in Collections:
Article: Metastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody
Title | Metastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody |
---|---|
Authors | |
Issue Date | 2012 |
Publisher | Scientific Research Publishing, Inc. The Journal's web site is located at http://www.scirp.org/journal/jct/ |
Citation | Journal of Cancer Therapy, 2012, v. 3 n. 6A, p. 902-911 How to Cite? |
Abstract | Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses. |
Persistent Identifier | http://hdl.handle.net/10722/180140 |
ISSN |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lam, KO | - |
dc.contributor.author | Lee, VHF | - |
dc.date.accessioned | 2013-01-21T01:29:55Z | - |
dc.date.available | 2013-01-21T01:29:55Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Journal of Cancer Therapy, 2012, v. 3 n. 6A, p. 902-911 | - |
dc.identifier.issn | 2151-1934 | - |
dc.identifier.uri | http://hdl.handle.net/10722/180140 | - |
dc.description.abstract | Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses. | - |
dc.language | eng | - |
dc.publisher | Scientific Research Publishing, Inc. The Journal's web site is located at http://www.scirp.org/journal/jct/ | - |
dc.relation.ispartof | Journal of Cancer Therapy | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Metastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody | - |
dc.type | Article | - |
dc.identifier.email | Lam, KO: lamkaon@hku.hk | - |
dc.identifier.email | Lee, VHF: vhflee@hku.hk | - |
dc.identifier.authority | Lam, KO=rp01501 | - |
dc.identifier.authority | Lee, VHF=rp00264 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.4236/jct.2012.326116 | - |
dc.identifier.hkuros | 212956 | - |
dc.identifier.volume | 3 | - |
dc.identifier.issue | 6A | - |
dc.identifier.spage | 902 | - |
dc.identifier.epage | 911 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 2151-1934 | - |